IMS Health Files for IPO
IMS Health has filed a registration statement with the US Securities and Exchange Commission
IMS Health, which provides information, services and technology for the healthcare industry, that allows them to measure and improve performance, has filed a registration statement with the U.S. Securities and Exchange Commission for proposed initial public offering of its common stock.
In the clinical trials area, IMS Health acquired both DecisionView and TTC in 2012. DecisionView provided software solutions for patient enrollment in clinical trials, and TTC benchmarking and analytics solutions for negotiating costs of clinical trials through its GrantPlan database.
The full relase can be read here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
